Abstract: Data objects can be migrated, while live, to virtualized clustered storage arrays in an efficient manner to allow for efficient transition from non-clustered storage to the virtualized clustered storage arrays. A data migration specification indicates data objects to be migrated and parameters for the migration. The parameters include a source of a data object, a destination of the data object in the virtualized clustered storage arrays, and a transfer space. A migration engine validates and parses the data migration specification. For each unique association of source, destination, and transfer space, the migration engine instantiates a migration process that drives and monitors migration of the corresponding data object. The migration processes operate in parallel for migration of the specified data objects into the virtualized clustered storage arrays.

Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.

Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.

Abstract: Data objects can be migrated, while live, to virtualized clustered storage arrays in an efficient manner to allow for efficient transition from non-clustered storage to the virtualized clustered storage arrays. A data migration specification indicates data objects to be migrated and parameters for the migration. The parameters include a source of a data object, a destination of the data object in the virtualized clustered storage arrays, and a transfer space. A migration engine validates and parses the data migration specification. For each unique association of source, destination, and transfer space, the migration engine instantiates a migration process that drives and monitors migration of the corresponding data object. The migration processes operate in parallel for migration of the specified data objects into the virtualized clustered storage arrays.

Abstract: Compounds represented by formula 1 can be potent and/or partially selective for the Kv7.2/7.3 heteromultimer. They may be useful in treating disorders related to seizures, pain, neurotransmitter release, etc.

Abstract: Data objects can be migrated, while live, to virtualized clustered storage arrays in an efficient manner to allow for efficient transition from non-clustered storage to the virtualized clustered storage arrays. A data migration specification indicates data objects to be migrated and parameters for the migration. The parameters include a source of a data object, a destination of the data object in the virtualized clustered storage arrays, and a transfer space. A migration engine validates and parses the data migration specification. For each unique association of source, destination, and transfer space, the migration engine instantiates a migration process that drives and monitors migration of the corresponding data object. The migration processes operate in parallel for migration of the specified data objects into the virtualized clustered storage arrays.

Abstract: Compounds having the formula I wherein Z, Z1 Z2 Z3, R3a, R3b and Rb and as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.

Abstract: Data objects can be migrated, while live, to virtualized clustered storage arrays in an efficient manner to allow for efficient transition from non-clustered storage to the virtualized clustered storage arrays. A data migration specification indicates data objects to be migrated and parameters for the migration. The parameters include a source of a data object, a destination of the data object in the virtualized clustered storage arrays, and a transfer space. A migration engine validates and parses the data migration specification. For each unique association of source, destination, and transfer space, the migration engine instantiates a migration process that drives and monitors migration of the corresponding data object. The migration processes operate in parallel for migration of the specified data objects into the virtualized clustered storage arrays.

Abstract: Articles and methods of manufacture are provided for using laser energy in an automated bonding machine to effect laser welding of ribbons to electronic components, particularly conductive ribbons comprising titanium for microelectronic circuits. Bonding and connection of microelectronic circuits with discrete heating avoids heat damage to peripheral microelectronic components. Bonding of flexible materials and low-resistance materials are possible, and are less dependant on substrate and terminal stability in comparison to other bonding methods. The ribbon-connections can forgo the use of blocks, bond pads, and bond pad arrays for attaching ribbon to a printed wiring board. Profile height of the ribbon-connection is decreased and the density of ribbons and bonding sites can be increased compared to ribbon-connections employing bonding pads.

Abstract: A system includes a storage engine node that includes a processor and a memory coupled to the processor. The memory stores a protocol mapper executable by the processor to convert storage access requests from a local storage protocol to a cloud storage protocol.

Abstract: Compounds of Formula I and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula I and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Abstract: The present invention provides thioalkeneamides of formula (I) which are useful as transketolase inhibitors: wherein R1, R2, R3, R4, R5, R6, Ra-Rd, n and ring A are as defined herein. The present invention also provides pharmaceutical compositions comprising the compounds of formula (I). The invention provides methods for inhibiting transketolase activity, reducing cellular ribose-5-phosphate levels, inhibiting nucleic acid synthesis, inhibiting cell proliferation and tumor cell growth in vitro and in vivo, stimulating apoptosis in tumor cells and treating cancer by administering a compound of formula (I) or a pharmaceutical composition thereof.

Abstract: Articles and methods of manufacture are provided for using laser energy in an automated bonding machine to effect laser welding of ribbons to electronic components, particularly conductive ribbons comprising titanium for microelectronic circuits. Bonding and connection of microelectronic circuits with discrete heating avoids heat damage to peripheral microelectronic components. Bonding of flexible materials and low-resistance materials are possible, and are less dependant on substrate and terminal stability in comparison to other bonding methods. The ribbon-connections can forgo the use of blocks, bond pads, and bond pad arrays for attaching ribbon to a printed wiring board. Profile height of the ribbon-connection is decreased and the density of ribbons and bonding sites can be increased compared to ribbon-connections employing bonding pads.

Abstract: The present invention provides N-3?-pyridyl-methyl or N-2?-pyrazinylmethyl thiazolium derivatives of formula (I) which are useful as transketolase inhibitors wherein R1, R2, R3, Y, R5-R9, Ra-Rd, n and X? are as defined herein. The present invention also provides pharmaceutical compositions comprising the compounds of formula (I). The invention provides methods for inhibiting transketolase activity, reducing cellular ribose-5-phosphate levels, inhibiting nucleic acid synthesis, inhibiting cell proliferation and tumor cell growth in vitro and in vivo, stimulating apoptosis in tumor cells and treating cancer by administering a compound of formula (I) or a pharmaceutical composition thereof.

Abstract: A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.

Abstract: The present invention provides thioalkeneamides of formula (I) which are useful as transketolase inhibitors: wherein R1, R2, R3, R4, R5, R6, Ra-Rd, n and ring A are as defined herein. The present invention also provides pharmaceutical compositions comprising the compounds of formula (I). The invention provides methods for inhibiting transketolase activity, reducing cellular ribose-5-phosphate levels, inhibiting nucleic acid synthesis, inhibiting cell proliferation and tumor cell growth in vitro and in vivo, stimulating apoptosis in tumor cells and treating cancer by administering a compound of formula (I) or a pharmaceutical composition thereof.

Abstract: Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Abstract: Compounds of Formula I and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula I and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Abstract: There is provided a CRF receptor antagonist comprising a compound of the formula (I): A-W—Ar??(I) wherein, A is a group represented by the formula (A1) or (A2): (wherein, ring Aa is a 5- or 6-membered ring which may be further substituted; ring Ab is a 5- or 6-membered ring which may be further substituted; ring Ac is a 5- or 6-membered ring which may be substituted; R1 is optionally substituted alkyl, substituted amino, substituted hydroxy, etc.; X is carbonyl, —O—, —S—, etc.; Y1, Y2 and Q are independently optionally substituted carbon or nitrogen; is a single or double bond); W is a bond, optionally substituted methylene, optionally substituted imino, —O—, —S—, etc.; Ar is optionally substituted aryl or optionally substituted heteroaryl; or a salt thereof or a prodrug thereof.

Abstract: A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, a method of antagonizing endothelin, methods for the inhibition of bone metastases, methods for the prevention of growth of new metastases, methods for the inhibition of bone turnover, and methods for the prevention of bone loss in patients, including cancer patients, using an endothelin ET-A receptor antagonist.